Acute kidney injury (AKI) is a common clinical syndrome with a broad aetiological profi le. It complicates about  of hospital admissions and  of admissions to intensive care units (ICU). During last  years has been a signifi cant change in the spectrum of severe AKI such that it is no longer mostly a single organ phenomenon but rather a complex multisystem clinical problem. Despite great advances in renal replacement technique (RRT), mortality from AKI, when part of MOF, remains over .
Introduction
Acute kidney injury (AKI) is defi ned as deterioration of renal function over hours, days to weeks. e mortality rate of AKI is - in intensive care unit (ICU) patients, and has not declined signifi cantly since the initial marked benefi t of acute dialysis therapy. Although multiple system organ failure (MSOF) and other comorbidities contribute to its high mortality rate, AKI independently increases morbidity and mortality. AKI-specifi c severity of illness scoring systems have been validated to predict prognosis in ICU AKI, accounting for both severity of renal failure and associated MSOF (,) . A prospective multicenter ICU study of AKI found that subjects with septic AKI had a far higher mortality rate ( vs , p < .) than those without sepsis () . Septic AKI is the dominant problem in managing ICU patients requiring renal replacement therapy (RRT) () .
When should RRT be started?
A number of the indications for RRT are uncontroversial, including uremic symptoms (anorexia, nausea, vomiting) or signs (bleeding, encephalopathy, uremic pericarditis), hyperkalemia refractory to medical management, volume overload unresponsive to fl uid restriction and diuretics, metabolic acidosis that is severe or accompanied by volume overload (precluding adequate bicarbonate therapy), certain dialyzable intoxications (e.g., lithium, salicylate, toxic alcohols), some cases of hypocalcemia, hyperphosphatemia, or hypercalcemia, and anuric AKI unresponsive to acute interventions (reversal of prerenal factors or relief of obstruction). Modern practice is to initiate RRT sooner rather than later, for example, when the SCr concentration reaches - μmol/l, perhaps even earlier, unless there is clear evidence that renal function is about to recover () .
Institution of RRT
The choice of the treatment will depend on the clinical practice, technical resources, and well-trained nurses of a given department, than on precise clinical indication. A proficient and accountable team, experienced in various dialytic modalities with a quality assurance education program would be ideal () . If this is not possible, the best combination of simple and easy treatment schedules, which are functional and efficient with no significant increases in personnel demand or labour intensity must suffice.
Biocompatibility
Two major studies found that use of biocompatible membranes improved these outcomes in AKI (,) . Several subsequent studies have failed to confi rm the benefi ts of biocompatibility in AKI, but have lacked the statistical power to defi nitively exclude any eff ect () . Use of a biocompatible dialyzer that also has higher "fl ux" (permeability) than the bioincompatible dialyzer may have infl uenced outcome in one study () . In light of a number of confl icting studies, the clinical relevance of this aspect of the acute dialysis prescription remains unproven, despite the fact that this strategy has already become standard in many centers () .
Dose of dialysis
e lack of a standardized measurement of RRT dose in AKI is a major defi ciency in the fi eld. Clearance of urea is the most commonly studied marker of adequate uremic detoxifi cation by IHD. e term Kt/V is a measure of the volume of plasma cleared of urea during an HD session (Kt) divided by the urea distribution volume (V, assumed to be total body water: .-. L/kg). e larger Kt/V values signify greater HD dose. Until further data is available, a reasonable recommendation off ered by the Acute Dialysis Quality Initiative is to deliver a dose of HD in the acute setting that is at least equal to what is considered acceptable in the chronic end-stage renal disease (ESRD) population. is is a Kt/V >. per treatment if IHD is provided three-times per week. Alternatively, one can attempt to deliver a Kt/V >. per treatment on a dialysis schedule of at least six days a week. Paganini et al.() demonstrated by retrospective analysis of a prospectively gathered database that delivered dialysis dose was predictive of mortality in critically ill ARI patients treated with RRT, if they had moderate-range severity of illness, but mortality of the most and least severely ill patients was independent of dialysis dose .
Choice of RRT
There are now many available options of RRT which may be divided into  groups: . peritoneal dialysis (PD), . IHD, . continuous therapies (CRRT), and . hybrid therapies (SLED). The ideal RRT should mimic the functions and physiological mechanisms of the native organ, ensuring qualitative and quantitative blood purifi cation, be free of complications, have good clinical tolerance and restore and maintain homeostasis, thus favouring organ recovery (Table ) . These  groups of RRT differ in the method of delivery, effi ciency, and their clinical tolerability. ere are certain clinical situations in which only a particular therapy is indicated (e.g., CRRT in critically ill patients with cardiovascular instability) () . Distinguishing whether AKI is a result of single organ dysfunction or part of MOF is a key factor. These two groups of subjects diff er substantially and should be treated differently. AKI without MOF is less complex, can be managed outside ICU and the same RRT techniques used for the treatment of chronic renal failure may be applied. AKI associated with MOF is a more complex condition and requires more fl exible RRT (,) .
Peritoneal dialysis
Acute PD remains a viable option for the treatment of selected patients with AKI, particularly pediatric population, and those who are hemodynamically compromised, have severe coagulation abnormalities, diffi culty in obtaining blood access, removal of high molecular weight toxins (> kD), and clinically signifi cant hypothermia and hyperthermia. ere are very few absolute contraindications for acute PD, most of the following conditions are only relative contraindications to this modality () . One of the important determinants of a successful acute PD procedure is a reliable peritoneal access, which can easily be obtained by inserting a semirigid acute catheter or a single cuff Tenckhoff catheter. Acute PD can be performed intermittently or continuously, and either manually or via an automated device. Complications of acute PD are numerous and potentially serious, but preventable, and include peritonitis, hyperglycemia, substantial protein loss, disturbance of respiratory mechanics, and visceral perforation while inserting the catheter () . Most studies have shown that the mortality and incidence of renal recovery with acute PD was at least comparable to IHD (,) .
Intermittent hemodialysis
ese technique require good vascular access, special equipment and specially trained physicians and nurses to carry out the dialysis. Patients that are hemodynamically stable can be managed with IHD techniques. Maintaining hemodynamic stability is probably one of the most important aspects of dialysis technique as well as one of the most diffi cult challenges. To improve hemodynamic tolerance of IHD, specific guidelines were implemented into practice (Table ) . e practice guidelines are based on dialysis strategies experienced in chronic HD patients suff ering from cardiovascular insuffi ciency. However, the targets for adequate solute clearance in AKI remain unknown, and the importance of removing middle and large uremic toxins in the setting of AKI remains to be determined. Consequently, physicians should consider empirical increases in dialytic time and IHD frequency and judicious use of anticoagulation to improve dialysis adequacy.
Continuous renal replacement therapies
With CRRT, the continuous regulation of volume homeostasis could lessen the hourly rate of required UF, thereby improving hemodynamic stability compared with IHD. Control of azotemia with modern veno-venous CRRT is at least equivalent to alternate-day IHD, and superior to daily IHD in large or hypercatabolic patients. Clinical data suggest that CRRT should be strongly considered for patients with severe hyperphosphatemia (tumor lysis syndrome, rhabdomyolysis), elevated intracranial pressure (ICP), cerebral edema complicating acute liver failure, might be a useful component of therapy for lithium intoxication, and because of continuous nature of process prevents the post-dialytic "rebound" elevation of plasma concentration of uremic toxins typically seen with IHD. e clinical benefi ts of CRRT have also been reported for cardiac surgery patients. CRRT appears to have benefi cial eff ects on hemodynamics in SIRS, sepsis or septic shock ( Figure ) . Although much attention has been focused on perceived benefits of CRRT compared with IHD, comparatively less attention has been focused on the potential for increased risks with CRRT therapy (Table  ) . In AKI patients stable enough to tolerate IHD, this benefit should be balanced against aspects of CRRT that might adversely aff ect outcome, such as continuous anticoagulation, prolonged membrane exposure, hypothermia, and nonselective removal of nutrients, infl ammatory mediators, and drugs. Despite apparent advantages over IHD in unstable patients, superiority of CRRT with respect to mortality or recovery of renal function has not been demonstrated. In patients AKI in the ICU patients is increasingly a component of SIRS, sepsis or septic shock, and the development of rational strategies for initiation, dosing, and eff ective delivery of RRT in this setting is among the greatest challenges facing nephrologists and intensivists today () . The use of CRRT is increasing in children and even newborns, and includes several modalities (CVVH, CV-VHD, and CVVHDF). In patients treated with CRRT, the rate of fluid and solute removal is slow and continuous. As a result, CRRT is better tolerated than IHD in patients who are hemodynamically unstable. The removal of solutes over the course of  to  hours is as efficient as conventional hemodialysis. In addition, some prefer this technique in patients with sepsis or MOF, as it may enhance the removal of cytokines.
'Hybrid' renal replacement therapies is technique utilizes equipmen t originally developed for treatment of patients with chronic renal failure and does not require industrially produced substitution fl uid.
e term "sustained low-effi ciency dialysis" (SLED) is the most widely used. is means of RRT combines several advantages of both IHD and CRRT, most notably excellent detoxifi cation and cardiovascular tolerability akin to that associated with CVVH. Machines for hybrid therapy should ideally have the characteristics like flexible options for dialysate flow (QD) (allowing for low fl ows should the clinical situation mandate low solute clearance and UFR), fl exible options for hybrid treatment duration (allowing prolonged or even continuous treatments), clear interface with the nurse managing the treatment preferably via a dedicated hybrid therapy screen, and standard procedures for changing between IHD and hybrid therapy (allowing either modality to be conveniently chosen at treatment commencement without any resultant delay) () (Figure ) . Different combinations of dry and liquid concentrates can be mixed allowing treatments to be tailored to the needs of individual patients. e extremely fl exible, yet highly efficient, SLED treatment modality fulfills all ICU requirements: it off ers immediate, highly eff ective dialysis therapy for acute hyperkalemia, whereas for less-urgent indications, treatment durations can be extended up to  h. Sustained low-effi ciency dialysis off ers several advantages over CRRT, including less cumbersome technique, patient mobility, and decreased requirements for anticoagulation, while providing similar hemodynamic stability and volume control. Several economic evaluations have shown SLED to be less expensive than CRRT. The Genius system consists of a single-pass batch dialysis machine that provides up to  L of an ultrapure germ-and endotoxin-free pure bicarbonate dialysate per dialysis session and a station for automated production of dialysate and filling of the machine. The technically simple machine has one roller pump in which both blood and dialysate tubing is inserted and that pumps blood and dialysate countercurrently with a ratio fi xed at : or :, depending on the diameter of the blood and dialysis tubing used. us, blood fl ow determines duration of treatment, ie, the time in which the  L dialysate tank is used up. Treatment time can be varied simply by changing the speed of the blood pump from  hours (conventional IHD with a : system and blood fl ow of  mL/min) to as much as  hours (extended dialysis with a : system and blood fl ow of  mL/min). e blood fl ow and treatment time may be modifi ed within treatment session.
e impact of dialytic modality on mortality and renal recovery Currently, it has been found no diff erence in mortality or renal recovery between hybrid RRT, CRRT or IHD for critically ill patients with AKI. However, future investigations should collect detailed information on long-term costs and the relative likelihood of renal recovery associated with dialysis modality. Until information from such a trial is available, a systematic review such as this may constitute the best possible evidence
List of Abbreviations

AKI
-acute kidney injury ICU -intensive care unit PD -peritoneal dialysis IH -intermittent hemodialysis CRRT -continuous renal replacement therapy
